Abcam, ab108905, Tissue type Plasminogen Activator Activity Assay Kit (Colorimetric, Human)

Size: 100Test
Tissue type Plasminogen Activator Activity Assay Kit (Colorimetric, Human) ab108905 is used to measure Human Tissue type Plasminogen Activator activity in serum and plasma.
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Serum,
Reacts with:Human,
Assay type:Enzyme activity (quantitative),
Sensitivity:= 0.13 IU/mL,
Range:0.156 - 40 IU/mL,
Assay time:1h,
Assay Platform:Microplate reader

Product details:
Tissue type Plasminogen Activator Activity Assay Kit (Colorimetric, Human) ab108905 is used to measure Human Tissue type Plasminogen Activator activity in serum and plasma samples.
The tPA assay protocol measures the ability of Tissue type Plasminogen Activator to activate the plasminogen to plasmin in coupled or indirect assays that contain Tissue type Plasminogen Activator, plasminogen, and a plasmin-specific synthetic substrate. The amount of plasmin produced is quantitated using a highly specific plasmin substrate releasing a yellow para-nitroaniline (pNA) chromophore. The change in absorbance of the pNA in the reaction solution at 405 nm is directly proportional to the Tissue type Plasminogen Activator enzymatic activity.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
Previously called Tissue type Plasminogen Activator Human Chromogenic Activity Assay Kit.
Tissue type Plasminogen Activator (tPA) is a 68 kDa serine protease that converts the zymogen plasminogen into the active serine protease plasmin which digests fibrin and induces the dissolution of fibrin clots. Tissue type Plasminogen Activator is synthesized by endothelial cells in normal blood vessels and displays relatively high affinity for fibrin, suggesting that it functions predominately in physiological thrombolysis in vivo.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions-Multi, Storage information-Please refer to protocols

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Tissue Plasminogen Activator (tPA) also known as a plasminogen activator acts mechanically to convert plasminogen to plasmin a serine protease. This reaction occurs at the surface of a fibrin clot leading to clot degradation a process known as fibrinolysis. tPA has a molecular mass of approximately 70 kDa. It is mainly expressed in vascular endothelial cells and is released into the bloodstream in response to stimuli such as circulatory stasis or endothelial damage.
Biological function summary
TPA plays a critical role in thrombolysis by breaking down blood clots into their soluble components. It regulates plasminogen function by cleaving this zymogen to yield the active protease plasmin. This function makes tPA integral in maintaining hemostasis and it does not form a part of a larger protein complex. The activity and the regulation of tPA are important for preventing pathologic clotting which can lead to cardiovascular complications.
Pathways
TPA is central to the fibrinolytic pathway. This pathway facilitates the conversion of plasminogen to plasmin enabling clot resolution. In addition tPA interacts with other proteins such as urokinase plasminogen activator (uPA) and inhibitors like plasminogen activator inhibitor-1 (PAI-1). The balance between tPA and its inhibitors is important for the regulation of fibrinolytic activity impacting hemostatic and thrombotic events.
TPA connects closely with conditions like stroke and myocardial infarction due to its thrombolytic properties. In ischemic stroke excessive or insufficient tPA activity can disrupt normal blood flow leading to tissue damage. Additionally in myocardial infarction tPA's role in breaking down clots proves important for restoring coronary blood flow. It is also linked with proteins like fibrinogen as they serve as substrates in the clot degradation process and with PAI-1 which modulates its activity and influences disease progression.